- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 209/34 - Oxygen atoms in position 2
Patent holdings for IPC class C07D 209/34
Total number of patents in this class: 550
10-year publication summary
|
55
|
34
|
30
|
38
|
44
|
20
|
35
|
34
|
29
|
20
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Boehringer Ingelheim International GmbH | 4486 |
19 |
| Georgetown University | 628 |
10 |
| Dana-Farber Cancer Institute, Inc. | 2666 |
7 |
| Ligand Pharmaceuticals Incorporated | 168 |
7 |
| Bayer Cropscience AG | 1836 |
6 |
| Board of Regents, The University of Texas System | 6141 |
6 |
| Arcus Biosciences, Inc. | 166 |
6 |
| ChemoCentryx, Inc. | 361 |
6 |
| Emory University | 1723 |
6 |
| Musc Foundation for Research Development | 369 |
6 |
| The Salk Institute for Biological Studies | 447 |
6 |
| Regenacy Pharmaceuticals, LLC | 26 |
6 |
| Novartis AG | 10173 |
5 |
| F. Hoffmann-La Roche AG | 7808 |
5 |
| The Board of Trustees of the University of Illinois | 2747 |
5 |
| Gilead Sciences, Inc. | 2236 |
5 |
| Honshu Chemical Industry Co., Ltd. | 193 |
5 |
| RespiVert Ltd. | 79 |
5 |
| NRG Therapeutics Ltd | 19 |
5 |
| Merck Sharp & Dohme LLC | 3737 |
5 |
| Other owners | 419 |